Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVALON is a line of hyaluronic acid-based dermal fillers developed by Koru Pharmaceuticals. It is composed of non-animal origin stabilized hyaluronic acid gel at a concentration of 20 mg/ml. The product is manufactured using proprietary MCO® Tech (Minimizing Cross-linking-agent by Optimizing reaction Technology), which minimizes the amount of cross-linking agents used while maintaining high efficiency and safety. AVALON is designed for intradermal and subdermal injection to correct wrinkles, restore facial volume, and perform facial contouring. The product line includes various formulations (Fine, Vital, Vital Plus, Ultra Plus) tailored for different injection depths and aesthetic needs, with some versions containing lidocaine for patient comfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AVALON.